All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F18%3A00078149" target="_blank" >RIV/00209805:_____/18:00078149 - isvavai.cz</a>

  • Result on the web

    <a href="https://www.sciencedirect.com/journal/physics-and-imaging-in-radiation-oncology" target="_blank" >https://www.sciencedirect.com/journal/physics-and-imaging-in-radiation-oncology</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.phro.2018.06.004" target="_blank" >10.1016/j.phro.2018.06.004</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas

  • Original language description

    Background and purpose: The amino-acid positron emission tomography (PET) tracer 3,4-dihydroxy-6-[18F] fluoro-L-phenylalanine (18F-DOPA) has increased sensitivity for detecting regions of biologically aggressive tumors compared to T1 contrast-enhanced (T1-CE) magnetic resonance imaging (MRI). We performed dosimetric evaluation of treatment plans prepared with and without inclusion of 18F-DOPA-based biological target volume (BTV) evaluating its role in guiding radiotherapy of grade III/IV gliomas. Materials and methods: Eight patients (five T1-CE, three non-contrast-enhancing [NCE]) were included in our study. MRI only-guided anatomic plans and MRI+18FDOPA-PET-guided biologic plans were prepared for each patient, and dosimetric data for target volumes and organs at risk (OAR) were compared. High-dose BTV60Gy was defined as regions with tumor to normal brain (T/N)&gt;2.0, while low-dose BTV51Gy was initially based on T/ N&gt;1.3, but refined per Nuclear Medicine expert. Results: For T1-CE tumors, planning target volumes (PTV) were larger than MRI-only anatomic target volumes. Despite increases in size of both gross target volumes and PTV, with volumetric-modulated arc therapy planning, no increase of dose to OAR was observed while maintaining similar target dose coverage. For NCE tumors, MRI +18F-DOPA PET biologic imaging identified a sub-region of the large, T2-FLAIR abnormal signal which may allow a smaller volume to receive the high dose (60 Gy) radiation. Conclusions: For T1-CE tumors, PTVs were larger than MRI-only anatomic target volumes with no increase of dose to OARs. Therefore, MRI+18F-DOPA PET-based biologic treatment planning appears feasible in patients with high-grade gliomas. 1. Introduction Evidence has emerged for a role of metabolic or biologic imaging in gliomas [1-4]. The amino-acid positron emission tomography (PET) tracer 3,4-dihydroxy-6-[18F] fluoro-l-phenylalanine (18F-DOPA) was found to have considerably increased sensitivity for detecting regions of biologically aggressive tumors compared to T1 contrast-enhanced (T1-CE) magnetic resonance imaging (MRI). In addition, T1-CE substantially underestimated the volume of the highly aggressive disease components [4]. Utilizing a derived threshold (uptake ratio of tumor to contralateral normal brain&gt;2.0), high uptake regions were identified outside of T1-CE in 8 of the 21 patients in our previous pilot study, including 3 non-contrast-enhanced (NCE) patients [4]. Ledezma et

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Physics and Imaging in Radiation Oncology

  • ISSN

    2405-6316

  • e-ISSN

  • Volume of the periodical

    6

  • Issue of the periodical within the volume

    April

  • Country of publishing house

    NL - THE KINGDOM OF THE NETHERLANDS

  • Number of pages

    7

  • Pages from-to

    94-100

  • UT code for WoS article

  • EID of the result in the Scopus database

    2-s2.0-85070485403